



Mesothelin and osteopontin

To the Editor:

The review by PANTAZOPOULOS *et al.* [1] on mesothelin and osteopontin was timely and well written. However, I would like to comment on some of the statements that were made. Firstly, it states that “patients with early-stage disease can survive for more than 5 years if the tumour is promptly resected”. This implies that resection would benefit the patient, which is far from proven; there is no randomised study showing this, except for the much criticised the Mesothelioma and Radical Surgery (MARS) study [2] in England, which showed that resection considerably shortened survival. The good survival seen by SUGARBAKER *et al.* [3] and in other studies can be explained by very strict selection and these patients are likely to survive at least as long without resection, as seen from studies where “operable” patients were treated conservatively. Furthermore, the authors claim that “early diagnosis offers the best hope for a favourable prognosis”, which is an interesting but unproven hypothesis. There is of course a lead time bias, the earlier the diagnosis the longer the survival, but unfortunately we do not know whether early intervention will in fact prolong survival. Thus, screening for mesothelioma in risk groups is not indicated at present, screening should only be performed in diseases where the prognosis has been shown to be improved by early discovery.

I fully agree with the other main conclusions in the review, namely that mesothelin, in serum or pleura, can be a useful aid in the diagnostic setup and also used for monitoring patients for recurrence.



@ERSpublications

Early stage mesothelioma and surgery: where do we stand?

<http://ow.ly/kRTJ2>

Gunnar Hillerdal

Dept of Pulmonary Medicine, Karolinska Hospital, Stockholm, Sweden.

Correspondence: G. Hillerdal, Karolinska Hospital, 17176 Stockholm, Stockholm, Sweden.

E-mail: gunnar.hillerdal@karolinska.se.

Received: March 23 2013 | Accepted: April 3 2013

Conflict of interest: None declared.

References

- 1 Pantazopoulos I, Boura P, Xanthos T, *et al.* Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41: 706–715.
- 2 Treasure T, Lang-Lazdunski L, Waller D, *et al.* Extra-pleural pneumonectomy *versus* no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. *Lancet Oncol* 2011; 12: 763–772.
- 3 Sugarbaker DJ, Flores RM, Jaklitsch MT, *et al.* Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. *J Thorac Cardiovasc Surg* 1999; 117: 54–63.

Eur Respir J 2013; 42: 557 | DOI: 10.1183/09031936.00052213 | Copyright ©ERS 2013

From the authors:

We would like to thank G. Hillerdal for his interest in our article [1] and for giving us the opportunity to make some comments regarding multimodality therapy and early stage disease.

SUGARBAKER *et al.* [2] reported a groundbreaking result in 1999: patients with early stage malignant pleural mesothelioma (MPM) had a 5-year survival rate after trimodality therapy that exceeded 40%. Since then, there have been a number of subsequent prospective and retrospective series, which have all demonstrated a median survival of 16.8–25.5 months [3–8]. Moreover, on September 11, 2012, in Boston (MA, USA) when the International Mesothelioma Interest Group met to discuss the role of surgery in the treatment of MPM, Valerie Rusch (New York, NY, USA) presented a preliminary analysis of the International Association for the Study of Lung Cancer (IASLC) staging project [9, 10]. In the IASLC worldwide registry of patients with all stages of epithelial MPM, the analysis showed a 19-month median survival among 1359 patients